NCT03600701 2025-10-07Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung CancerNational Cancer Institute (NCI)Phase 2 Active not recruiting51 enrolled